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Abstract
Background: Expression of the urokinase plasminogen activator receptor (UPAR) has been shown
to have clinical relevance in various cancers. We have recently identified UPAR as an asthma
susceptibility gene and there is evidence to suggest that uPAR may be upregulated in lung diseases
such as COPD and asthma. uPAR is a key receptor involved in the formation of the serine protease
plasmin by interacting with uPA and has been implicated in many physiological processes including
proliferation and migration. The current aim was to determine key regulatory regions and splice
variants of UPAR and quantify its expression in primary human tissues and cells (including lung,
bronchial epithelium (HBEC), airway smooth muscle (HASM) and peripheral cells).
Results: Using Rapid Amplification of cDNA Ends (RACE) a conserved transcription start site (-
42 to -77 relative to ATG) was identified and multiple transcription factor binding sites predicted.
Seven major splice variants were identified (>5% total expression), including multiple exon
deletions and an alternative exon 7b (encoding a truncated, soluble, 229aa protein). Variants were
differentially expressed, with a high proportion of E7b usage in lung tissue and structural cells (55–
87% of transcripts), whereas classical exon 7 (encoding the GPI-linked protein) was preferentially
expressed in peripheral cells (~80% of transcripts), often with exon 6 or 5+6 deletions. Real-time
PCR confirmed expression of uPAR mRNA in lung, as well as airway and peripheral cell types with
~50–100 fold greater expression in peripheral cells versus airway cells and confirmed RACE data.
Protein analysis confirmed expression of multiple different forms of uPAR in the same cells as well
as expression of soluble uPAR in cell supernatants. The pattern of expression did not directly
reflect that seen at the mRNA level, indicating that post-translational mechanisms of regulation may
also play an important role.
Conclusion: We have identified multiple uPAR isoforms in the lung and immune cells and shown
that expression is cell specific. These data provide a novel mechanism for uPAR regulation, as
different exon splicing may determine uPAR function e.g. alternative E7b results in a soluble isoform
due to the loss of the GPI anchor and exon deletions may affect uPA (ligand) and/or integrin binding
and therefore influence downstream pathways. Expression of different isoforms within the lung
should be taken into consideration in studies of uPAR in respiratory disease.
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Background
The plasminogen pathway and specifically the urokinase
plasminogen activator receptor (uPAR) has been of inter-
est in the cancer field for some time (reviewed in [1,2]).
The uPAR protein has been shown to be over-expressed in
many different cancers [2], whilst an exon 4–5 deleted
mRNA has been shown to be over-expressed in breast can-
cer [3].
The uPAR protein is a modulator of the plasminogen
pathway, which cleaves and activates urokinase (uPA) [4].
uPAR-uPA is involved in the proteolytic activation of plas-
minogen to plasmin, which in turn degrades fibrin and
other ECM components and activates matrix metallopro-
teases. However uPAR has many other roles (reviewed in
[5,6]), acting via both intra- and extra- cellular signalling
pathways. For instance, soluble uPAR fragments have
chemotactic activity [7], whilst uPAR interacts with
integrins [8] and G-protein coupled receptors to signal
within the cell via intracellular kinases. These many inter-
actions explain the position of uPAR as a key player in tis-
sue remodelling, proliferation and cell migration, in both
normal and disease states [5].
A key feature of many respiratory diseases, including
asthma, is airway remodelling [9]. From the known biol-
ogy of uPAR, this receptor is potentially involved in tissue
remodelling and may be predicted to influence decline in
lung function, due to its role in ECM remodelling, prolif-
eration and migration of several cell types [10]. Recently
we have performed linkage and association analyses uti-
lising three populations including 587 UK and Dutch
asthma families and identified the urokinase plasmino-
gen activator receptor gene (uPAR or PLAUR) as an asthma
susceptibility gene [11]. We have shown that single nucle-
otide polymorphisms (SNPs) spanning UPAR determine
the rate of decline in FEV1 and are also determinants of
soluble uPAR in the serum of asthma subjects [11]. In
addition, uPAR has been shown to be up-regulated in
lung epithelium in severe/fatal asthma [12], whilst solu-
ble uPAR was found to be elevated in the sputum in mul-
tiple respiratory diseases (asthma, chronic obstructive
pulmonary disease (COPD) and cystic fibrosis) [13]. A
gene profiling study also showed uPAR expression was
related to reduced lung function in COPD patients, with
increased staining for the uPAR protein in the airway epi-
thelium of airflow obstructed patients [14]. Therefore our
previous data and data from others suggest that levels of
uPAR expression may be important in multiple respira-
tory diseases.
The uPAR protein has three domains and is bound to the
membrane via a glycosylphosphatidylinositol (GPI)
anchor; however it may also be found as a soluble form
due to cleavage of the GPI anchor and both membrane
bound and soluble forms may be cleaved by various pro-
teases, including uPA to give D1 and D2/3 fragments [15].
The human airway trypsin-like protease (HAT) expressed
in airway epithelium can cleave both membrane bound
and soluble uPAR at the D1/D2 linker [16], resulting in
release of the D1 fragment. The mature uPAR protein con-
sists of three similar domains which assemble to create a
globular structure almost surrounding a central cavity in
which uPA binds [17,18]. Specific residues have been
determined to be involved in binding uPA [17,19] and
integrins [20,21] as well as having chemotactic functions
[22] (Figure 1).
The UPAR gene consists of seven exons. Exon 1 encodes
the 5'UTR and a signal peptide, whilst exons 2–3, 4–5 and
6–7 encode the homologous protein domains D1, D2 and
D3 [23]. Use of an alternative exon 7 (described hereafter
as exon 7b) has been reported and results in replacement
of the terminal 75 amino acids with a novel 21 residues;
this variant cannot gain a GPI anchor and thus encodes a
soluble form of the receptor [24]. Variants lacking exons 5
and 4+5 have also been described [3,22,23]. The exon 5
variant was originally identified from a HeLa cDNA
library whilst the exon 4+5 deletion was identified in var-
ious cancer cell lines using a limited PCR design. To date
no comprehensive evaluation of splice variation of uPAR
has been completed.
Due to the increasing interest in uPAR expression in lung
diseases, the current study aimed to characterise the UPAR
gene and identify cell specific transcription initiation sites
as well as to identify and quantify splice isoforms in cells
and tissues from the lung and periphery. These data pro-
vide definitive answers regarding the type and extent of
uPAR splice variation and generate a greater insight into
the molecular mechanisms underlying the expression and
activity of uPAR in the normal lung and immune cells,
which may in turn have implications for the role of this
receptor in airway disease.
Results
UPAR has a localised transcriptional start site that shows 
limited cell specificity
The transcriptional start sites (TSS) for UPAR were deter-
mined by 5' RACE in a panel of six human tissues/cell
types (Figure 2A). In lung tissue, human airway smooth
muscle cells (HASM), polymorphonuclear cells (PMN)
and peripheral blood mononuclear cells (PBMC), the
dominant TSS was located at -46 to -52 bp relative to the
start codon, however the major TSS in differentiated
human bronchial epithelial cells (HBEC) was at -75 bp
and a further two minor sites were identified at -42 to -44
(in PMN/PBMC) and at -64 to -69 (all except differenti-
ated HBEC). Differences in TSS usage between tissues/
cells were significant (Chi-square, p < 0.001). A shortlistBMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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of transcription factors relevant to respiratory disease and
asthma was generated by reference to the literature and a
4 kb upstream fragment analysed for potential transcrip-
tion factor binding sites using four different on-line data-
bases. Consensus sites for c/EBP (9), AP-1 (1), GATA (9),
NF-AT (2), STAT (6) and RXR (1) were identified (Figure
2B).
uPAR is expressed in multiple splice forms in the lung and 
periphery
To identify splice variants and determine the exon struc-
ture of uPAR, 5' and 3' RACE were completed in six differ-
ent tissues/cell types (Figures 2 and 3). 5' RACE identified
a localised TSS (see earlier) and demonstrated that exons
1 and 2 were conserved in all cells/tissues (data not
shown). An exon 3 deletion variant was identified at low
frequency in differentiated HBEC (4.5% of clones
sequenced), PMN (4.5%) and PBMC (4.3%). 3' RACE
confirmed the expression of the classical exon 7 as well as
the alternative exon 7b, which was present with a trun-
cated or extended 3'UTR (Figure 3). The pattern of expres-
sion of splice variants differed between tissues/cell types
(Chi-square p < 0.001). Several exon deletion variants
were identified including; exon 5, 6 and 5+6 deletions,
although only the exon 6 deletion had a frequency >5%
(Figure 3). In addition PCR products spanning exons 1–7
and 1–7b were cloned and sequenced to determine which
exon deletions were found in combination with the two
alternative terminal exons, demonstrating that an addi-
tional exon 4+5 deletion exists (data not shown). Interest-
ingly, the structural cell types (HASM, HBEC) and lung
appeared to express mostly exon 7b (55–87% of clones
sequenced), encoding a soluble variant of uPAR, whilst
more classical membrane bound uPAR (≈ 80%) was
detected in the peripheral cells (PMN and PBMC) (when
all exon deleted forms were pooled). In RACE, exon-
deleted transcripts were cloned from all cell types except
differentiated HBEC and HASM. These results were con-
firmed by full-length PCR, when no exon-deleted forms
were obtained for differentiated HBEC and 2/48 clones
for HASM, which would not have been detectable by
RACE based on primer design (del3 and del4+5). Lung tis-
sue showed 8% exon deleted clones in the RACE analysis;
these were exon 5 or 6 deletions, in combination with
exon 7b. Of the lung cells, undifferentiated HBEC showed
the largest number of exon-deleted forms (7/44 clones
Schematic representation of uPAR structure Figure 1
Schematic representation of uPAR structure. UPAR consists of seven exons, with an alternative exon 7b previously 
reported [24]. The classical form is transcribed to give a three domain protein which can be membrane bound, via a GPI 
anchor. Domain S: Signal peptide removed during processing, Domain G: removed during processing to give GPI anchor at new 
C-terminus. Different regions of each domain involved in various protein-protein interactions are highlighted, which may give 
an indication of the functions of variant forms of the receptor. uPA binding involves residues in all three domains (see Figure 4), 
with key binding regions in D1 and D2 [17,19]. The minimum chemotactic sequence is located in the D1-D2 linker [22], A 
region implicated in binding integrins α1β3 and α5β1, aiding signalling to vitronectin, which also has chemotactic activity is 
located in D2 [20]. A region in D3 which binds integrin α5β1 is also highlighted [21].
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analysed, 16%), which included three unique clones
showing non-classical splice sites (data not shown). The
two peripheral cell types analysed showed high frequen-
cies of exon deleted forms in the RACE analysis (PMN: 14/
22, 64%; PBMC: 10/21, 48%). These were predominantly
exon 6 deletions, although del5 and del5+6 were also
observed. PCR analysis of PBMC confirmed these data
with 16/24 exon1–7 clones showing exon deletions
(including del6 (5/24), del5 (4/34) and del5+6 (3/24))
and 4/24 exon 1–7b clones showing deletions (including
del6 (1/24) and del5 (2/24)). All classical exon deletions
are in frame deletions. See Table 1 for molecular details of
splice variation and Figures 4 and 5 for predicted protein
sequences.
Real-time quantitative PCR confirms uPAR splice variants 
and identifies cell-specific expression
In order to confirm and quantify the expression of differ-
ent uPAR variants at the mRNA level, a series of real-time
PCR assays were designed to amplify uPAR exons 1–2
(conserved, total uPAR), 1–7 and 1–7b, whilst a series of
deletion-specific probes allowed detection of variants
(Table 2 and Figure 6). Two different normalising or
housekeeping assays, 18s ribosomal RNA and hypoxan-
thine guanine phosphoribosyltransferase 1 (HPRT1),
were tested and showed similar results (data not shown).
However, HPRT1 was used in the main analysis as its level
of mRNA expression was more comparable to that of
uPAR itself.
Real-time PCR was performed using cDNA from eight tis-
sues/cell types in total, from either one (lung and brain)
or two (HASM, HBEC, PMN, PBMC) donors, or prepared
from RNA extracted on two different occasions for cell
lines (THP1 (monocyte), BEAS2B (bronchial epithe-
lium)). Total uPAR expression was confirmed in the lung
tissue and varied in a cell-type specific pattern; PMN ≥
PBMC>>lung>HBEC≈HASM>BEAS2B≈THP-1 (ANOVA p
= 0.013), the HASM and HBEC expression levels being
~100 fold lower than primary peripheral cells (PMN and
PBMC) (Figure 7A). Expression was very low in brain (6-
fold less than cultured cells).
Overall, expression levels of classical uPAR (exon 7) cor-
relate with total uPAR levels, PMN ≥
PBMC>>lung>HBEC≈HASM>BEAS2B≈THP1 (Pearson r =
0.891, p = 0.003), suggesting that this may be the domi-
nant expressed variant (Figure 7A and 7B). Exon deleted
versions of classical uPAR were also confirmed (Figure 7C
– E). Exon 6 deletions were widely expressed with an
expression profile similar to classical uPAR (exon 7)
expression, whilst exon 3 and 5+6 deletions were detected
only in PMN and PBMC, with some donor specific varia-
tion (Figure 7D and 7E). Unlike total or classical uPAR
Identification and characterisation of the uPAR promoter Figure 2
Identification and characterisation of the uPAR promoter. (A) 5' RACE performed on a panel of tissues/cell types 
identified a cluster of transcriptional start sites (TSS) which show distinct patterns of usage. TSS are listed relative to ATG of 
translated sequence. (B) 4000 bp upstream (from ATG) was analysed for potential transcription factor binding sites using four 
different programs. Those sites identified in two or more different searches are shown.
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which were much more highly expressed in peripheral
cells, alternative uPAR (E7b) was expressed in
lung>PBMC>HASM≈HBEC>THP1≈BEAS2B (Figure 7F).
Expression of this variant did not correlate with total
uPAR expression. Exon 4+5 deletions were detected in all
cells expressing uPAR(E7b) with expression
HASM>lung≈HBEC>BEAS2B≈PBMC>THP1 (Figure 7G).
Classical uPAR exon 5 and 4+5 deletions and alternative
uPAR exon 5 deletion were not detected (data not
shown).
Normalisation of these data for total uPAR expression
allowed direct comparison with our previous RACE data
which highlighted proportional expression of different
splice variants in tissues/cells (Figure 8). The correlation
between RACE data (Figure 3) and classical uPAR propor-
tional expression (Figure 8A) was not clear as it may be
expected that the proportional expression of this isoform
should be elevated in e.g. PBMC/PMN vs. lung/HASM/
HBEC as shown in the absolute expression data (Figure
7A). However, uPAR(E7b) was proportionally highly
expressed in cultured cells (THP1 and BEAS2B) > lung,
HASM and HBEC (about 2/3×) >> (1/50×) PBMC (not
detected in PMN) (ANOVA not significant) (Figure 8E).
These data correspond with RACE data (Figure 3), suggest-
ing lower proportional expression of this variant in pri-
mary peripheral cells versus lung cells and highlighted
differences between cultured cell lines (BEAS2B, THP1)
and the equivalent primary cells i.e. HBEC and PBMC.
Comparison of the proportional expression of the exon
4+5 deleted uPAR(E7b) form to total uPAR(E7b) expres-
sion, suggests lower expression in lung, PBMC and THP1
than HASM, HBEC and BEAS2B (Figure 8F), potentially
suggesting that this splicing event occurs preferentially in
structural cells. The predicted protein sequences of all
confirmed splice variants are shown in Figures 4 and 5.
Protein analysis confirms the existence of multiple forms 
of uPAR
To determine whether the variation in uPAR isoforms at
the mRNA level was reflected at the protein level, total cell
lysates were assayed using two uPAR specific antibodies in
Western blots. Lysates from two donors or extractions
(cell lines) were assayed (except for commercial lysates:
PMN and PBMC). Representative results are shown in Fig-
ure 9. Western blots performed with either domain 1 or
domain 2 specific antibodies detected multiple proteins
in all samples (Figure 9A and 9B, summarised in Table 3).
Controls using no primary antibody or an isotype control
showed no binding to either a THP1 cell lysate or recom-
binant uPAR (data not shown). Loading was evaluated
using β-actin and was equivalent for key comparisons e.g.
between PBMC and THP1 and between HASM, HBEC and
BEAS2B (Figure 9C).
Predicted sizes for all variants detected by real-time PCR
suggested that multiple variants between 60–100% of the
full length classical uPAR should be detected in all cell
types (Table 4). It should be noted that additional mRNA
species were detected by PCR and RACE which were not
analysed by real-time PCR, therefore more species may
actually be present in cells. However, the abundance of
these transcripts in RACE was low (<5%). The epitope of
the D1 antibody is located at amino acids 52–60 (exon 2–
3) therefore this antibody will detect all variants except
exon 3 deletions and D2/3 proteolysis fragments. The
epitope of the D2 antibody is located at amino acids 125–
132 (exon 4) therefore this antibody will not detect exon
4 deleted variants or D1 proteolysis fragments. Glycosyla-
tion of uPAR occurs at asparginine residues located at
amino acids 52 (located in D1, exon3), 162 (D2, exon 5),
172 (D2, exon 5) and 200 (D3, exon 6) and shows site
specific heterogeneity, generating multiple different
molecular weight forms [25]. This may result in a wide
range of proteins on Western blotting.
Table 1: Alternative uPAR splicing identified in the RACE analyses
Variant 5'Donor site 3'Acceptor site Implication
E3 deletion GCGCTTGTGGGAAG GCCGGGCTGTCAC In frame deletion, removal of 48 residues
E4+5 deletion CCAGGGCAACTCTG TCCTGGAGCTTGA In frame deletion, removal of 100 residues, valine insertion
E5 deletion AGGTGAAGAAG TCCTGGAGCTTGA In frame deletion, removal of 46 residues, valine insertion
E6 deletion
(with E7)
CAACGAGGGCCCAA AACCGAAAAACC In frame deletion, removal of 50 residues, lysine insertion
E6 deletion
(with E7b)
CAACGAGGGCCCAA AACGCTCACTCTGG In frame deletion, removal of 50 residues, lysine insertion
E5+6 deletion
(with E7)
AGGTGAAGAAG AACCGAAAAACC In frame deletion, removal of 94 residues
E3+4+5 deletion GCGCTTGTGGGAAG TCCTGGAGCTTGA In frame deletion, removal of 148 residues, valine insertion
uPAR variants detected at >5% frequency in RACE analysis are included.BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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Full-length uPAR protein has a predicted molecular
weight of 31 kDa, however differential glycosylation pat-
terns result in a size range of 40–60 kDa. Recombinant
uPAR expressed in a mouse melanoma cell line was
included and was detected between 45–60 kDa with both
antibodies. The D2 specific antibody also detected a
higher molecular weight protein (70–75 kDa), possibly
representing a dimerisation or aggregation product. A
lower molecular weight protein was also observed (30–35
kDa), which probably corresponds to a D2/3 proteolytic
fragment.
The D1 antibody detected fewer proteins than the D2 anti-
body (including for the recombinant protein) (Figure
9A). D1 proteolytic fragments (expected molecular weight
10–20 kDa) were not detected, probably due to their rela-
tively small molecular weight. The highest molecular
weight protein seen in all cell types (60 kDa) probably
represents full-length classical uPAR as it corresponds
most closely to the band observed for recombinant uPAR
and by others [26-28]. Proteins are seen around 50 kDa
for all except PMN and PBMC cells, suggesting that these
may represent the alternative exon 7b form (expected
Identification of 3' variants in a panel of tissues/cell types Figure 3
Identification of 3' variants in a panel of tissues/cell types. 3' RACE was performed on a panel of tissues/cell types using 
a uPAR-specific forward primer located in exon 4. Frequencies of the most common variants (>5% overall expression) in each 
cell type based on numbers of RACE clones are summarised (A) and their structures shown (B). "Other" variants include both 
alternative termination sites and splice variants. Grey blocks highlight 3' UTR in the terminal exon.
A 
 
Expression in different tissues/cell types (% and (number of clones analysed))  Expressed form
 
Lung  HASM  HBEC undiff  HBEC diff  PMN PBMC 
1: E7b short  54 (20)  18 (6)  66 (29)  67 (14)  14 (3)  24 (5) 
2: E7 (classical)  24 (9)  15 (5)  7 (3)  14 (3)  14 (3)  19 (4) 
3: E7b long  3 (1)  56 (19)  11 (5)  19 (4)  5 (1)  0 
4: E6 del, E7   0  0  2 (1)  0  45 (10)  33 (7) 
Others
  19 (7)  12 (4)  9 (4)  0  23 (5)  24 (5) 
 
B 
 
 
 
  
 
1
2
3
4
Frequently 
expressed 
variants 
(>5% total) 
273-277 bp 
563-564 bp 
443-453 bp 
563-564 bp 
 
Exon:   4  5  6  7  7b 
Exon length (bp):  162 135  147  564  430  BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
Page 7 of 19
(page number not for citation purposes)
~90% of the mass of classical uPAR). The slightly smaller
fragments detected in PMN and PBMC cells only (desig-
nated 45 kDa) may represent single exon (e.g. exon 6)
deletions of classical uPAR (expected ~80% of the mass of
classical uPAR). A protein at 37 kDa is detected in all cell
types except HBEC, being particularly strongly expressed
in PMN and PBMC. This could represent dual exon dele-
tions (e.g. classical uPAR, exon 5+6 deletion), although its
pattern of expression does not completely correspond to
that seen at the mRNA level. The smallest protein seen (30
kDa) may represent an alternative exon 7b, exon 4+5
deleted form (expected ~55% of the mass of classical
uPAR), although this might be expected to be expressed in
a greater number of cell types.
The D2 antibody detects three proteins in the recom-
binant sample, probably reflecting a dimerisation, full-
length uPAR and a D2/3 proteolytic fragment (Figure 9B).
The large (75 kDa) protein is detected in the majority of
cell types, being most strongly expressed in PBMC and
THP1 cells. HBEC lysates showed less abundant proteins
at lower molecular weights than other structural cell
lysates, reflecting the pattern using the D1 antibody,
although overall it is difficult to make direct comparisons
between the two blots.
The expression of soluble PAR was detected in the super-
natants of all cells tested (Figure 9D). Overall, higher lev-
els of soluble uPAR were observed in supernatants from
BEAS2B and THP1 cells compared to HASM and HBEC.
Interestingly, in the proportional mRNA level analyses,
Protein sequences of uPAR exon 7 splice variants Figure 4
Protein sequences of uPAR exon 7 splice variants. Alternate splice variants which were identified and confirmed by real 
time PCR in the current analyses are shown. Alternate exons are labelled back and blue; red amino acids are encoded over an 
exon boundary. The signal peptide, removed during processing (not included in numbering of mature peptide) is highlighted 
green. The region highlighted pink is removed during processing to give GPI anchor at the new C-terminus. Domains are 
defined by the end cysteines involved in disulphide bridges (purple). Peptide D2A (yellow, domain 2) binds integrins αvβ3 and 
α5β1, aiding signalling to vitronectin and also has chemotactic activity [20], whilst a region highlighted in domain 3 (yellow) 
binds integrin α5β1 [21]. The minimum chemotactic domain (turquoise) binds FPRL1 and encourages chemotaxis of many cell 
types [22]. uPA binding regions determined by phage display and peptide array are highlighted grey [19], whilst residues 
involved in the uPA binding determined by alanine scanning mutagenesis are highlighted red [17].
A. Full length uPAR (classical variant, membrane bound) 
 
Exon1             Exon2         Domain1                     Exon3 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHS 
   Domain1                     Exon4   Domain2 
EKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSP 
                  Exon5      Domain2                            Exon6 
EEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLP 
          Domain3                               Exon7 
QNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSM 
Domain3 
NHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT 
 
 
B. Full length uPAR (alternative E7b variant, soluble)  
 
Exon1             Exon2         Domain1                     Exon3 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHS 
   Domain1                     Exon4   Domain2 
EKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSP 
                  Exon5      Domain2                            Exon6 
EEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLP 
  Domain3(?)             Exon7 
QNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHERSLWGSWLPCKSTTALRPPCCEEAQATHV BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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Protein sequences of uPAR internal exon splice variants Figure 5
Protein sequences of uPAR internal exon splice variants. Alternate splice variants which were identified and confirmed 
by real time PCR in the current analyses are shown. A signal peptide removed during processing (not included in the number-
ing of mature peptide) is highlighted green and the terminal domain (pink) is removed during processing to give a GPI anchor at 
the new C-terminus.
A. Exon3del (classical variant, membrane bound) 
 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWE 
[Exon del] 
GRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDD
RHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNS
THGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHI
DVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT 
 
B. Exon5+6del (classical variant, membrane bound) 
 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEE  [exon del] 
EPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPG
PAHLSLTITLLMTARLWGGTLLWT 
 
C. Exon6del (classical variant, membrane bound)  
 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPK  [exon del] 
PKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGP
AHLSLTITLLMTARLWGGTLLWT 
 
D. Exon4+5del (alternative E7b variant, soluble)  
 
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNS [exon del] 
VLELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHERSLWGSWLPC
KSTTALRPPCCEEAQATHV BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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BEAS2B and THP1 were shown to express a greater pro-
portion of the alternative, soluble form (exon 7b) com-
pared to HASM and HBEC (Figure 8E).
siRNA confirms the specificity of anti-uPAR Western blots
Western blotting using two monoclonal antibodies for
uPAR detected multiple bands. To confirm that these
bands represent uPAR variants, siRNA was performed in
undifferentiated HBEC cells. Cells were treated with
siRNA (negative control, uPAR-specific (S032) or a uPAR-
specific panel (mix)) for 24 hours before RNA and protein
were extracted and analysed by real-time PCR and West-
ern blotting (Figure 10A). Total uPAR mRNA expression
was measured by real-time PCR, showing about 50%
knockdown with both siRNA strategies (Figure 10B).
Total uPAR protein expression detected by the domain 1
(IIIF10) and domain 2 (3932) antibodies is also reduced
(Figure 10A) which was confirmed by densitometry anal-
ysis, before and after normalisation to β-actin (Figures
10C and 10D respectively). The domain 2 specific anti-
body detected three main species, which were all shown
to be knocked down at the protein level by at least one
siRNA approach using densitometry (Figure 10D).
Discussion
The expression and functional activity of uPAR is of inter-
est in both cancer and respiratory disease. The current
study aimed to characterise the key regulatory regions of
UPAR, identify all common splice variation and quantify
expression in the normal lung and in specific lung and
peripheral cells at the mRNA and protein levels. We have
identified a localised TSS with some cell specificity and
confirmed expression of uPAR in lung and peripheral
cells. At the mRNA level, multiple uPAR splice variants
were identified including alternative E7 (E7b) and dele-
tions of E3, E5+6 and E6, and their patterns of expression
in different tissues/cell types characterised. Primary
peripheral cells (PMN and PBMC) expressed multiple
exon deleted forms of membrane bound uPAR, whilst
lung cells including epithelium and airway smooth mus-
cle expressed a greater proportion of an alternative soluble
uPAR with and without an exon 4+5 deletion. Protein
analyses confirmed expression of multiple differentially
expressed forms of uPAR in all cell extracts, and soluble
uPAR was detected in the supernatants of cultured HASM,
HBEC, THP1 and BEAS2B cells. Specificity of the Western
blotting analyses was confirmed by siRNA. Our data pro-
vide a novel insight into the molecular mechanisms that
potentially regulate uPAR expression and activity in the
airways and the periphery which has implications regard-
ing the potential role of uPAR in airway disease biology.
Previous analyses in cell lines suggested the TSS of UPAR
is 52 bp upstream of the ATG, with a minor start site
Table 2: Primers and probes for RACE and real-time PCR
Primers
Assay Primer Position Sequence
RACE 5'RACE nested 48852556 CCTCTCACAGCTCATGTCTGAT
RACE 5'RACE 48852500 ACCACATCCAGGCACTGTTCTTC
RACE 3'RACE 48852519 GAACAGTGCCTGGATGTGGTGAC
PCR/Real-time uPAR Fwd E1 48866085 CTGCTGCTGCTCCACACCT
PCR/Real-time uPAR Rev E7 48845002 TGGGTGGTTACAGCCACTTT
PCR/Real-time uPAR Rev E7b 48842344 ATCACATCTGCTGGGGCTAC
PCR/Real-time uPAR Rev E2 48863624 ACTCTTCCACACGGCAATCCC
PCR/Real-time uPAR Rev E7b
(long UTR)
48842223 GCCTGTCCTTCCATGATGTT
Probes
Assay TaqMan Probe Location Sequence ('denotes exon boundary)
Real-time PCR Exon 1–2 Exon1–2 CCAGCCTCTTGGGGCCTGCGGT
Real-time PCR Exon 5 del Exon4–6 AGCTCCAGGA'CTTCTTCACCTTCC
Real-time PCR Exon 3 del Exon 2–4 CAGCCCGGC'CTTCCCACAAGCG
Real-time PCR Exon 6 del +E7 Exon 5–7 TTCGGTT'TTGGGCCCTCGTTGCAT
Real-time PCR Exon 6 del +E7b Exon 5–7b TTCCCCAGAGTGAGCGTT'TTGGGC
Real-time PCR Exon 5+6 del +E7 Exon 4–7 TCCAGGAAGGTGAAGAAG'AACCGAAA
Real-time PCR Exon 5+6 del; E7b Exon 4–7b CCCAGAGTGAGCGTT'CTTCTTCACC
Real-time PCR Exon 4+5 del Exon 3–6 TGCAACCAGGGCAACTCTG'TCCT
Primers listed for RACE were used with RACE-specific primers from GeneRacer kit (Invitrogen). Other primers were used to amplify full-length 
uPAR for both standard PCR and real-time assays. All TaqMan probes were labelled with Fam and TAMRA and were used with appropriate 
primers. Primer location is listed relative to chromosome 19 reference sequence for the start of the primer.BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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around -77 bp in U937 (monocytes) and HeLa (epithe-
lial) cells [29]. We have now confirmed and extended
these initial analyses using tissues and cells of the respira-
tory and immune systems; namely lung, HASM, HBEC,
PMN and PBMC. In all samples the TSS was located
between -42 and -77, however there were clear cell specific
locations within this interval i.e. -46 to -52 is the domi-
nant TSS in most cells and lung tissue but not in HBEC
where the -75 to -78 locus is dominant. The functional sig-
nificance of the cell specific TSS usage remains to be
resolved although it is interesting to note that functional
studies using promoter-reporter approaches have sug-
gested that most transcriptional activity is found in the
first 220 bp upstream of the ATG in HeLa, HCT116 and
RKO (colon cancer) cells [29-31]. Functional studies have
implicated AP1 (-122) and SP1-like motifs (spanning -
139 to -154) as being important for basal uPAR transcrip-
tion in colon cancer and HeLa cells [29,30]. We used data-
mining to characterise relevant transcription factor bind-
ing sites in the 4 kb promoter region identifying a number
of different potential pro-inflammatory transcription fac-
tor binding sites including AP1, STAT, GATA and CCAAT/
EBP sites using two or more databases. Only a single AP1
(-236) site and no SP1 sites were replicated, despite their
known importance, indicating that some sites may be
missed using our replication strategy, however, the AP1 (-
122) and SP1 (-151) sites identified in functional studies
were detected by individual databases. uPAR expression
has been shown to be regulated by a number of growth
factors at the transcriptional level, which include TGFβ1
utilizing the AP1 site at -236 [32]. TGFβ1 is a pro-fibrotic
cytokine that has been implicated in airway remodelling
in asthma and therefore it is tempting to speculate that
TGFβ1 induction of uPAR may be a significant mecha-
nism involved in airway remodelling.
The second objective of the current study was to deter-
mine uPAR splice variation in airway and peripheral cells
using real-time PCR. Two donors were used for each cell
type (but not tissues), to allow for inter-individual differ-
Location of Taqman primers and probes Figure 6
Location of Taqman primers and probes. Variants shown were identified in one or more clone and in one or more cell 
type during RACE/PCR analyses. Location of primers and probes generating variant specific TaqMan assays are indicated.
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Full length E7 
Full length E7b 
(short or long UTR) 
Exon 5 del (E7) 
Exon 5 del (E7b) 
Exon 3 del (E7) 
Exon 3 del (E7b) 
Exon 6 del (E7) 
Exon6 del (E7b) 
Exon 5-6 del (E7) 
Exon 5-6 del (E7b) 
PCR primer position 
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Expression of uPAR splice variant mRNA in different tissues/cell types Figure 7
Expression of uPAR splice variant mRNA in different tissues/cell types. A series of real-time PCR (TaqMan) assays 
was used to measure the expression of different splice variants of uPAR in an extended panel of tissues/cell types (lung, brain, 
HASM, undifferentiated HBEC, BEAS2B, PMN, PBMC, THP1). Expression of each variant is shown as mean + SEM of three 
PCR replicates, for two donors or biological replicates as appropriate. Data are shown as 2-ΔCt normalised to HPRT1 and rela-
tive to a suitable plasmid positive control containing the specific splice variant cDNA (designated 100%). (A) total uPAR, (B) 
total classical uPAR (exon 7), (C) classical uPAR exon 6 deletion, (D) classical uPAR exons 5+6 deletion, (E) classical uPAR 
exon 3 deletion, (F) total alternative uPAR (exon7b), (G) alternative uPAR exon 4+5 deletion. Classical uPAR exon 5 and 4+5 
deletions and alternative uPAR exon 5 deletion were not detected.
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Expression of different uPAR splice variant mRNAs in different tissues/cell types normalised to total uPAR Figure 8
Expression of different uPAR splice variant mRNAs in different tissues/cell types normalised to total uPAR. A 
series of real-time PCR assays was used to measure the expression of different splice variants of uPAR in an extended panel of 
tissues/cell types (lung, brain, HASM, undifferentiated HBEC, BEAS2B, PMN, PBMC, THP1). Expression of each variant is 
shown as mean + SEM of three PCR replicates, for two donors or biological replicates as appropriate. Data are shown as 2-ΔCt 
normalised to total uPAR and relative to a suitable plasmid control (designated 100%). (A) total classical uPAR (exon 7), (B) 
classical uPAR exon 6 deletion, (C) classical uPAR exons 5+6 deletion, (D) classical uPAR exon 3 deletion, (E) total alternative 
uPAR (exon7b), (F) alternative uPAR exon 4+5 deletion. Classical uPAR exon 5 and 4+5 deletions and alternative uPAR exon 
5 deletion were not detected.
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ences. We observed expression of the previously identified
uPAR E7b soluble splice variant [24], which is predicted
to result in the loss of the GPI anchor, in the lung and
periphery. Interestingly the primary peripheral cells
expressed low levels of this variant (as a fraction of total
uPAR) compared to the lung tissue and cells. This suggests
that peripheral cells could retain more of their uPAR at the
cell membrane (GPI-bound) whilst lung structural cells
produce more soluble, secreted uPAR. Binding of uPA to
membrane bound uPAR initiates many intracellular sig-
nalling pathways, resulting in outcomes including differ-
entiation, proliferation and cell motility [5], whilst
soluble uPAR can act as a chemoattractant for hematopoi-
etic cells [33]. It is therefore possible that airway cells
might express more soluble uPAR to allow them to attract
cells into the airways, whilst the peripheral cells express
mainly the surface form of the receptor to allow them to
respond to external signals.
In addition to the exon7 variants we also identified a
series of internal exon deletion variants expressed within
the context of both the membrane bound and soluble
receptor. These included exon 3, 4+5, 5+6 and 6 deletions.
Exon deleted forms of classical uPAR were found most fre-
quently in the primary peripheral cells, PMN and PBMC.
Exon 6 deletion was the most widely expressed. Loss of
exon 6 would disrupt the structure of D3, particularly as it
includes one of the key cysteines involved in disulphide
bonding. This would be expected to lead to reduced uPA
binding affinity [19] as two amino acid residues shown to
be involved in uPA binding are located in this exon [17].
Expression of an exon 4+5 deleted variant of uPAR has
previously been described and was shown to be associated
with shorter disease-free survival in breast cancers using a
real-time PCR strategy [3], however the assay used did not
distinguish between exon 7 variants. In the present study,
we did not detect this deletion in combination with clas-
sical exon 7 using real-time PCR (although a single clone
was obtained from PBMC by PCR), whereas in combina-
tion with alternative exon 7b this variant was detected in
most tissues/cell types, notably the structural cells HASM,
HBEC and BEAS2B. Based on the known structure of
uPAR, this variant might express a soluble form of the
receptor lacking the key chemotactic sequence [22] and
D2, which includes integrin binding domains [20]. Some
uPA binding ability conferred by D1 may be retained [19]
although many uPA binding residues will be lost [17] and
the structure of the protein [18] will be compromised. It is
possible that this form might act as a dominant-negative
inhibitor of uPAR action, by sequestering uPA and pre-
venting its binding to full length membrane-bound or sol-
uble forms of the receptor.
Repeated epithelial wounding/repair leading to airway
remodelling has been implicated in asthma pathogenesis
[34]. Epithelial cells have the capacity to repair by cell
spreading, migration and proliferation, all integrin-
dependent processes. Integrins have therefore been sug-
gested to play a prominent role in wound repair in asthma
and the expression of α3β1 (laminin receptor) and α5β1
(fibronectin receptor) integrins have been shown to be
upregulated at epithelial wound edges [35,36]. uPAR
interacts with integrins (mainly α3β1 and α5β1) and has
been shown to influence cell adhesion and migration on
ECM proteins [37,38]. Therefore the identification of
splice variants that lose this ability to bind integrins (i.e.
exon 5 deletions) may be of significance in normal and
disease mechanisms.
At the protein level, multiple forms of uPAR were detected
in cell lysates. Overall, our data suggest that multiple
forms of uPAR are expressed in the panel of cells studied
Table 3: Identification of proteins in Western blots
ruPAR HASM HBEC BEAS2B THP1 PMN PBMC Predicted variants
70 70 dimer/aggregates
50–60 60 60 55–60 60 60 60 full length
anti-D1 (55-50) 50 (50) alternative ex7b
(IIIF10) (kDa) 45 (45) single exon deletion (e.g. exon 3 or 6)
(37) (37) 37 37 37 two exon deletions (e.g. exon 5+6)
30 (30) alternative ex7b, exon 4+5deletion
75 (75) (75) 75 75 dimer/aggregates
anti-D2 50–55 60 (60) 60 60 50 full length
(3932)
(kDa)
45 45 45 45 45 45 single exon deletion or alternative ex7b
(40) 40 40 two exon deletions
(37) 37 (37) 37 37 37 alternative ex7b, exon 4+5deletion or D2/3 fragment
Western blots were performed using two antibodies specific to domains 1 and 2 of the uPAR protein respectively (Figure 9). The main proteins 
observed in each cell or tissue type with each antibody are summarised. Approximate molecular weights of bands are shown (kDa), with weaker 
bands shown in brackets and the strongest band in bold. Potential splice variants for each molecular weight are also shown.BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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and there is some evidence of differential expression. This
corresponds to the findings of Brooks et al. [27], who
showed predominantly lower molecular weight forms of
uPAR to be expressed in peripheral neutrophils, whilst
higher molecular weight forms were more highly
expressed in lung eosinophils. These data are also in keep-
ing with our mRNA analyses which suggested a higher
proportion of exon deletion variants are expressed in the
periphery, potentially resulting in lower molecular weight
proteins.
Although the majority of high abundance predicted uPAR
variants might be expected to be detected using either the
D1 or D2 antibody, the patterns of expression observed
were markedly different. This could reflect differing affin-
ities of the two antibodies for different variants. It should
be noted that the epitope for the D1 antibody (amino
acids 52–60) corresponds to one of the potential glyco-
sylation sites for the protein (Asn52) [25]. The presence of
a large carbohydrate side-chain may prevent binding of
the antibody, resulting in detection of fewer forms by this
antibody as we have observed. Additionally, the D1 anti-
body will not detect D2/3 proteolytic fragments, explain-
Expression of uPAR protein in different cell types Figure 9
Expression of uPAR protein in different cell types. Western blotting of cell lysates was performed for an extended panel 
of cell types (HASM, undifferentiated HBEC, BEAS2B, THP1, PMN, PBMC) plus recombinant uPAR (ruPAR) using domain I 
specific (A) and domain II specific (B) antibodies to identify different variants. A β-actin antibody was used as a loading control 
(C). An ELISA assay, with a sensitivity of 30 pg/mL, was used to detect soluble uPAR in the culture supernatant where appro-
priate (D).
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ing the presence of fewer low molecular weight proteins
detected using this antibody. An attempt has been made
to mirror patterns of protein expression as determined by
Western blot to real-time PCR results, with some success
for the D1 antibody results e.g. the presence of a 50 kDa
protein potentially representing the alternative exon7b
observed in all cell types except PMN and PBMC, as well
as a 45 kDa form seen only in PBMC and PMN which may
represent single exon deletions of classical uPAR. Con-
cordance between the two assays may be affected by dif-
fering efficiencies of the real-time PCR assays or antibody
specificity. However, it will also reflect genuine biological
differences, as post-translational control mechanisms
including glycosylation and proteolytic cleavage play a
key role in uPAR protein maturation [15,25]. Our data
reflect this complex regulatory pathway.
All cultured cells tested showed expression of soluble
uPAR. This assay does not distinguish between classical
uPAR released from its GPI anchor, proteolytic fragments
and alternatively spliced (exon 7b) soluble uPAR. How-
ever, all of these cell lines expressed relatively high pro-
portions of alternative uPAR(E7b) mRNA and the level of
mRNA correlates with soluble uPAR protein expression
e.g. BEAS2B and THP1 had elevated alternative
uPAR(E7b) mRNA and soluble uPAR protein. Therefore,
the elevated levels of uPAR in the sputum of asthma and
COPD subjects may reflect expression of soluble uPAR
from both epithelial and smooth muscle cells.
Conclusion
We have identified the key promoter region of UPAR in
the airway and highlighted potential regulatory transcrip-
tion factor binding sites. We have identified multiple
splice variants with potentially different functional activ-
ity including soluble expression and/or the loss of key
binding domains, such as those involved in ligand bind-
ing or integrin interactions. The expression patterns of
these splice variants in airway and peripheral cells provide
an insight into the molecular mechanisms regulating
uPAR expression and activity. These data highlight the
importance of uPAR splice variants, which should be
taken into consideration in future work to determine the
role of uPAR in respiratory disease.
Methods
Cell culture, preparation of total RNA and cell protein 
lysates and siRNA knock-down
Primary human airway smooth muscle (HASM) cells were
isolated and prepared as described previously [39] and
cultured in DMEM + 10% foetal calf serum (FCS). Airway
smooth muscle cells from two individuals were used.
BEAS-2B (airway epithelial cells) were cultured in DMEM
+ 10% FCS, whilst THP1 (monocyte) cells (ATCC) were
cultured in modified RPMI 1640 medium + 10% FCS +
0.05 mM β-mercaptoethanol. Human bronchial epithe-
lial cells (HBEC) from two donors were obtained from
Lonza (Wokingham, UK) and cultured in bronchial epi-
thelial growth medium (BEGM). Cells were differentiated
at an air-liquid interface using bronchial epithelial differ-
entiation medium (BEDM) as described previously [40].
Table 4: Predicted protein sizes and antibody specificity
Variant Size (aa)* Predicted MWt (kDa) Predicted expression (real-time PCR)
HASM HBEC BEAS2B PBMC PMN THP1
Classical 283 31.5 ++ ++ + +++ +++ +
Alternative Exon7 259 28.9 +++ +++ ++ +++ - ++
Classical del3 235 26.2 - - - ++ ++ -
Classical del5+6 189 21.2 - - - ++ ++ -
Classical del6 234 26.1 ++ ++ + +++ +++ +
Alternative del 4+5 160 17.8 +++ +++ ++ ++ - +
D1 fragment 83/89 9.8 ++ ++ ++ ++ ++ ++
Classical D2/3 196 21.8 ++ ++ + ++ ++ +
Alternative D2/3 172 19.2 ++ ++ ++ ++ - ++
* After removal of signal peptides
Predicted protein translations were performed for variants detected in real-time PCR assays (Figures 4 and 5) and predicted molecular weights 
(MWt, kDa) obtained. Note that these are potentially about 10 kDa smaller than might be detected at the protein level due to glycosylation. For 
each variant, relative expression based on real-time PCR results is summarised where +++: highest expression, ++: expression, + low expression 
and -: not detected. Other variants were detected in RACE experiments, which may result in expression of additional protein variants. Note that 
the D1 antibody would detect all variants except exon 3 deletions and D2/3 fragments, whilst the D2 antibody would not detect exon 4 deletions 
or the D1 fragment.BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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siRNA knockdown of uPAR in human bronchial epithelial cells Figure 10
siRNA knockdown of uPAR in human bronchial epithelial cells. HBEC were treated with siRNA (negative control, 
uPAR specific (S032) or pooled siRNA panel (mix)) for 24 hours before RNA and protein extraction. Western blotting was 
performed using two different anti-uPAR antibodies and an anti-β-actin antibody. Recombinant uPAR (ruPAR) was run as a 
control (A). Real-time PCR was performed using a total uPAR assay and normalised using HPRT as a housekeeping gene (B). 
Densitometry was performed on Western blots (regions measured shown boxed) to allow semi-quantitative measurement of 
knockdown. Data are shown before (C) and after (D) normalisation for β-actin expression. The anti-D2 antibody detected 
multiple different weight species. Densitometry was performed for individual bands and normalised for β-actin expression (D).
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For downstream analysis, cells were lysed and RNA
extracted using silica columns (RNeasy mini kit, Qiagen,
Crawley, UK). For protein analysis, cell lysates were pre-
pared using cytobuster buffer (Novagen, Merck, Notting-
ham, UK) with benzonase (Merck) and complete protease
inhibitor (Roche, Welwyn Garden City, UK), as directed
by the manufacturer. Ethical approval for the use of pri-
mary cells was obtained from the Nottingham University
Hospitals local ethical committee.
uPAR was targeted for knockdown in undifferentiated
HBEC cells using siRNA specific to exon 1 (S032) or a
panel of four siRNAs specific to exons 1–2, 7 and 7b
(mix). Silencer select negative control #1 was used as a
control. siRNA sequences available on request. Silencer
select siRNAs were obtained from Applied Biosystems
(Warrington, UK). Cells were plated in 6-well plates at
100,000 cells per well and transfected after 48 hours with
10 nM total siRNA using 5 μl Liopfectamine 2000 as
directed by the manufacturer (Invitrogen, Paisley, UK).
Peripheral cell preparation
Whole blood was collected from healthy volunteers (45
ml). Red blood cells were removed using dextran sedi-
mentation, before separating the neutrophils (PMN) and
mononuclear cells (PBMC) by centrifugation in a discon-
tinuous percoll gradient. Slides were prepared by cytospin
for characterisation of cell populations. PMN were >95%
pure (some eosinophils and basophils), whilst PBMC
consisted mostly of lymphocytes (44%) and monocytes
(39%) with the remainder eosinophils and neutrophils as
defined by morphology. Ethical approval was obtained
from the Nottingham University Hospitals local ethical
committee. RNA was prepared as described previously.
RNA and lysates from PMN and PBMC were also obtained
commercially (3 H Biomedical, Uppsala, Sweden).
Rapid amplification of cDNA ends (RACE)
RACE-ready cDNA was synthesised from total RNA (1 μg)
(PMN, PBMC, HASM, differentiated and undifferentiated
HBEC and commercially obtained lung (Ambion,
Applied Biosystems)) using the GeneRacer kit as directed
(Invitrogen). 5' and 3' RACE used GeneRacer primers and
uPAR exon 4 specific nested primers for amplification
(Table 2). Full-length uPAR PCR products generated using
primers specific to exon 1 and 7 or 7b were also cloned to
further clarify the exon structure of the gene. Both RACE
products and PCR products were sequenced using BigDye
3.1 (Applied Biosystems) in conjunction with an ABI 310
DNA sequencer. Sequences were aligned to the human
database using BLAST but also compared to known uPAR
transcripts and each other using EMBL-EBI's multiple
alignment tool, ClustalW http://www.ebi.ac.uk/clustalw.
Alignments were made against reference sequences
NM_002659.2 (classical E7) and NM_001005376 (alter-
native E7b).
Real-time PCR
mRNA levels of total uPAR and splice variants were quan-
tified using a series of real-time PCR assays. Amplicons
spanning exons 1–2, 1–7 and 1–7b were used in combi-
nation with a series of splice-variant specific FAM/TAMRA
labelled TaqMan probes to define up to 16 different vari-
ants (Table 2, Figure 6). For each splice variant, PCR prod-
ucts were cloned and sequenced to generate a positive
control and standard. cDNA was synthesised using Super-
script II (Invitrogen) and random hexamer primers as per
instructions. RNA (0.7 μg) was used in a 20 μl reverse
transcription reaction. Real-time PCR was performed
using TaqMan gene expression master mix (Applied Bio-
systems) and 18s ribosomal RNA or HPRT1 endogenous
control (Applied Biosystems). Data was corrected using
the housekeeper (18s or HPRT1) and the 2-ΔCt method
and normalised to a variant specific positive control plas-
mid. Alternative splice variants were also normalised to
total uPAR to identify proportional expression and allow
comparison to RACE data.
Western blotting
Lysates of cultured cells and commercially obtained PMN
and PBMC protein lysates were separated by 10% SDS-
PAGE under reducing conditions. Proteins were trans-
ferred to a PVDF membrane and probed using two anti-
uPAR antibodies; uPAR D1 monoclonal: IIIF10 (Santa
Cruz Biotechnology, Heidelberg, Germany) 0.25 μg/ml
(1:400) and uPAR D2 monoclonal: 3932 (American Diag-
nostica, Axis-Shield UK, Kimbolton, UK) 2.5 μg/ml
(1:200) with an appropriate HRP-conjugated secondary
antibody (R&D systems, Abingdon, UK) (1:1000). Bind-
ing was visualised by enhanced chemiluminescence (ECL,
Amersham Biosciences, GE healthcare, Little Chalfont,
UK). Membranes were stripped using Restore Western
blot stripping buffer (Thermo Fisher Scientific, Perbio Sci-
ence UK, Cramlington, UK) and re-probed for β-actin
expression (ab8227, Abcam, Cambridge, UK, 1:5000) as a
loading control. Antibody dilutions were based on manu-
facturers' recommendations. Densitometry of protein
bands was completed using ImageJ 1.41 http://
rsbweb.nih.gov/ij/.
Enzyme-linked immunosorbent assay (ELISA)
The uPAR Duoset ELISA kit (R&D systems) was used to
quantify soluble uPAR in cell culture supernatants, fol-
lowing the manufacturer's recommendations. uPAR was
quantified using tetramethylbenzidine (R&D systems)
and a MultiscanEX plate reader (Thermo Fisher Scientific)
at 450 nm with 570 nm background subtraction. The
detection limit of the assay was 30 pg/mL sample.BMC Molecular Biology 2009, 10:75 http://www.biomedcentral.com/1471-2199/10/75
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In silico promoter analysis
Transcription factors relevant to respiratory disease and
asthma were identified by reference to the literature (AP1,
NFKB, NF-AT, CREB, STAT, C/EBP, GR, RXR, SRC-1, TIF-
2, p/CAF, CBP, GATA)[41,42]. A 4000 bp fragment
upstream of the transcriptional start site was analysed for
potential transcription factor binding sites using four dif-
ferent algorithms available online, as described previously
[39]. Results of these searches were compared and those
binding sites identified in two or more different searches
were included in a final summary.
Statistical analysis
Differences between RACE results were evaluated using
contingency tables (Chi-square test). Differences in
expression in real-time PCR experiments were evaluated
using ANOVA and Tukey's post hoc test. Data were ana-
lysed using Prism v.5.01 (GraphPad software, La Jolla,
CA). P < 0.05 was considered significant.
Abbreviations
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